Skip to Content

Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers

DESTINY-Brest03 was a prospective randomized phase 3 clinical trial that aimed to compare the efficacy of trastuzumab deruxtecan (T-DXd) with that of trastuzumab emtansine (T-DM1) in patients suffering from HER2 positive metastatic breast cancers.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top